Cord blood (CB), Bone Marrow (BM) and Peripheral Blood (harvested after specialised processes) are known to contain potentially life-saving hematopoietic-mesenchymal progenitor stem cell (HSCs and MSCs) populations with superior and long-term marrow establishing activities. These adult marrow derived cells offers an excellent alternative source of stem cells for cellular and regenerative therapy. CB/BM-HSCs can reconstitute the depleted bone marrow in the adults and therefore used in Marrow transplantations and replacements. CB/BM stem cells can be cultured, induced, and trans-differentiate into desirable cell types to replace lost cells and tissues.
In India, HSCT based applications to treat the haematological indications, including entire spectrum of blood cancers, hemoglobinopathies, anaemia’s, blood disorders etc are approved as a standard therapy, with the market trend suggesting 1 million requiring this therapy every year. Akrivis has been forefront in generating HSCT technology and is following the universal standard of generating sufficient cells, 3 x 108 Nucleated Cells/kg of the body, for transplantation requirements.
In India, HSCT implementation is not matured enough and is in the laboratory scale only. To meet the demand, we have proposed herewith an industry model, wherein a centralised, regulated processing centre will generate Stem Cells (HSCs) for various indications. The Cord Blood or any HSC source will be collected from the Cord Blood Banks, Referral Hospitals or Government health care institutions. The product will be shipped to the end user.
Motoneuron Diseases, Inflammatory Bowl Diseases, Crohns, Wound healing, Prevention of organ rejections, GVHD, Anti-aging, and Cosmetic Applications. The demand for hypoxic MSCs are so huge that almost 2/5 of the world’s regenerative therapy demand is met by these cells. Currently, the world’s production of hypoxic MSCs is chiefly depending on fetal tissue, which is unreliable, and marred with ethical, safety and teratogenic issues.
Hypoxic MSCs from Akrivis hiMSCTM Technology are derived from adult human tissues thereby making it one of the safest, reliable and acceptable technology for universal regenerative applications. Hypoxic Stem Cell production through hiMSCTM Technology is a complex, Multilayered Technology Platform involving a Series of technological perfections in each stage of production. The unique multi-step culture - independent advanced isolation technologies produces one of the world’s highly stem-cell enriched, ̴61.5%, clinical grade therapeutic products (Fig 1) that are 20 times highly productive than other international products, and 6000 times enriched from an average stem cell percentage (o.o1%) exist in adult bone marrow (Fig 1) and produces cells with high ALDH Expression, an undisputed marker for stem cells (Fig 2) with superior regenerating capacities, and superior expression of Growth factors and Cytokines.
Dendritic Cell (DC) therapy represents a promising immune therapeutic approach for the treatment of cancer and other disorders. The characteristic of DC therapy is that it exploits the body's own immune system to promote desirable results. Though the first generation technologies have been developed a decade ago, the efficacy and clinical outcome of the trials and therapies are far from satisfactory, partly due to the complexity of the cancer and the protocols that are employed to generate DC cells. First and Second generation protocols are therefore inherently defective, used certain factors in cultures that induced tolerance to tumor antigens resulting in poor clinical outcomes and abrogation of DC effects. Furthermore, the pleotrophic effect of DC activation is difficult to control within the body, prompting us to work on the optimal cellular source, the type of DC produced and the protocol employed. Realising the need for a better DC technology, AKRIVIS has produced a unique DC-TechnologyTM population that has desired inductive properties, T cell activation and polarising abilities.
Akrivis DC-TechnologyTM combines the features of easy accessibility of DC source from peripheral blood and defined processes to generate desirable populations. A unique “three step protocol technology” uses features that are consistent to the natural DC cell activation and maturation, yet leaving aside the harmful and negative impacts of certain activation factors. Close attention has been given to elicit a defined Th polarisation response, superior cytokine productions and migration efficiency of the DC that are produced from the DC-TechnologyTM.
Akrivis DC-TechnologyTM has modular aspects, one activation sequence followed by other. Depending upon the necessity and nature of cure, such sequences and durations can be modified without compromising on the quality of the DCs being transplanted. This gives the flexibility of time and cost overruns as this are extremely a complex and expensive process.
Biomarker-driven precision medicine (personalized medicine) is fundamentally changing life sciences research. Central to biomarker research is access to quality biospecimens in biobanks that have been extensively annotated with clinical, molecular, and patient data.
Biobanks are no longer measured by how many samples they keep, but by the utilization of these samples to drive investigational research. This shift poses challenges for traditional, first-generation biobanks. Next Generation Biobanking not only supports operational activities, but also functions as the knowledge hub for an integrated translational and clinical research ecosystem. With the Next Generation Biobanking approach, you will reap the benefits of a well-annotated patient and sample database that supports precision medicine, clinical trials, translational research, and patient registries.
A biobank is a liability, not an asset – unless and until it can provide significant value for scientific research. Traditional biobanking faces a number of challenges resulting from the pressure of biomarker-based precision medicine research:
Medical technology encompasses a wide range of health care products and, in one form or another, is used to diagnose, monitor or treat every disease or condition that affects humans. These innovative technologies are improving the quality of health care delivered and patient outcomes through earlier diagnosis, less invasive treatment options and reductions in hospital stays and rehabilitation times.
Medical technology innovations are fundamentally transforming the health care landscape, providing new solutions to address chronic diseases conditions and revolutionize the way treatments are administered. Miniature robots capable of performing complex spinal surgery, noninvasive treatment of brain tumors with a focused beam of gamma radiation, and light-activated drugs that target diseased cells are examples of breakthrough technologies that have recently made the leap from medical fantasy to medical reality.
Future medical technology breakthroughs will build from the incredible progress made in other scientific and technical areas, harnessing the increasing power and sophistication of computers, advancements in communications capabilities, and the information learned from deciphering the human genome. Future innovations in medical technology will reflect several broad trends:
Health information technology innovations will allow critical medical data to be processed and transmitted rapidly over great distances, saving both patients and physicians time and speeding delivery of treatment.
Delivering advanced medical technologies into the hands of patients, physicians and other end users is a continual and complex process. The incremental nature of medical technology innovation and the wide range of device types pose unique challenges for innovators, unlike those faced by the pharmaceutical or biologics sectors.
The medical technology innovation process is interactive and involves significant collaboration with physicians and other end users. Real-world experiences with a product, both positive and negative, are critical to the design of the next generation of a technology.
The field of Health Policy and Systems Research (HPSR) is currently experiencing an unprecedented level of interest. The First Global Symposium on Health Systems Research, held in Montreux, Switzerland, in November 2010, is the most recent of a succession of conferences and task force deliberations that have spun off a series of debates about the nature of the field and the future directions it should take. Establishing the identity and terrain of HPSR is part of these debates, which is made difficult by the fact that it is an essentially multidisciplinary field delimited not by methodology but by the topic and scope of research questions asked. In this paper, the first of a series of three addressing the current challenges and opportunities for the development of HPSR, we introduce and map the types of research questions that it has addressed over its natural course of evolution, analyze the nature of current heightened attention, and highlight emerging opportunities and challenges for the development of the field.
We use the extended term Health Policy and Systems Research for a field that is often referred to simply as Health Systems Research. For us, the broader term better captures the terrain of work it encompasses because it explicitly identifies the interconnections between policy and systems, and highlights the social and political nature of the field. The geographical focus of our concern is low- and middle-income countries (LMICs) but we suggest that our approach also has value for high-income countries. Our understanding of the evolution of HPSR draws primarily from the English language literature, which we acknowledge as a limitation. However, this reflects global discussion about the field, which has tended to neglect literature in other languages.
Anyone taking a cursory glance at current pharmaceutical industry revenue forecasts could be forgiven for thinking that all is well. However, the assumptions behind these numbers do not adequately take into account two seismic shifts that are disturbing the industry status quo. The first shift is in the balance of power across the healthcare value chain, as governments and insurers take center stage, pressuring pharmaceutical companies to reduce prices and demonstrate greater value from their therapies. Secondly, we believe a swing from treatment to prevention, diagnostics and cure, will grow stronger in time, attracting a host of new entrants from within and outside of the sector
With rising demand for healthcare and falling budgets, governments and payers
are exerting pressure to drive down prices. One bold example involves the Netherlands. Not content
with striking volume deals with the major pharmaceutical players, it is looking to utilize the
power of the EU to create even greater economies of scale. At the moment, several member states are
pooling together into a single procurement machine with much greater bargaining power.1 This
initiative, in its early stages, is also being looked at by other states seeking to cut their drug
expenditure. Additionally governments, insurers and patients are requiring greater transparency
around drug pricing.
The time-honored healthcare principle of fee-for-service is also under
attack. Payers, insurers and hospitals are no longer willing to pay simply for a product push
approach; they want fees to be dependent upon the success of the products and procedures through
measurable outcomes. The mobile revolution has irrevocably changed the way the world communicates.
The initial contours of this change were felt in the social dimension, where communication barriers
between individuals were eased. Over time, fueled by fertile minds, the contours extended to the
business dimension, where greater effectiveness was achieved by establishing a personal connection
with customers, which hitherto was almost impossible in some industry segments, such as
pharmaceuticals.
The mobile revolution has irrevocably changed the way the world communicates. The initial contours of this change were felt in the social dimension, where communication barriers between individuals were eased. Over time, fueled by fertile minds, the contours extended to the business dimension, where greater effectiveness was achieved by establishing a personal connection with customers, which hitherto was almost impossible in some industry segments, such as pharmaceuticals.
Health information technology innovations will allow critical medical data to be processed and transmitted rapidly over great distances, saving both patients and physicians time and speeding delivery of treatment.
Delivering advanced medical technologies into the hands of patients, physicians and other end users is a continual and complex process. The incremental nature of medical technology innovation and the wide range of device types pose unique challenges for innovators, unlike those faced by the pharmaceutical or biologics sectors.
The medical technology innovation process is interactive and involves significant collaboration with physicians and other end users. Real-world experiences with a product, both positive and negative, are critical to the design of the next generation of a technology.
Create a distinct persona for your healthcare service or product. Get the market edge by proper brand positioning to maximize the ROI on your marketing.
Our healthcare application services are aimed at automating and streamlining your medical practices for improved performance.
We can help you leverage the reach of mobile to deliver healthcare mobility solutions that are scalable, secure and device agnostic.
Market your product or services to the right audience at the right time. Get a 360° marketing strategy for your healthcare brand online.
We can host your healthcare software securely on the cloud and do away with expensive upgrades, migrations and server costs.
Our exclusive partnership with leading 3D animation providers helps us in delivering world-class medical animation and illustrations for training videos and books.
